Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2013	FY 2012
Period Ending	Dec 31, 2013	Dec 31, 2012
Cash & Equivalents	0.79	1.6
Cash & Short-Term Investments	0.79	1.6
Cash Growth	-50.69%	-
Other Receivables	0.09	0.16
Receivables	0.09	0.16
Prepaid Expenses	0.01	-
Other Current Assets	0.04	0.03
Total Current Assets	0.93	1.79
Property, Plant & Equipment	0.01	0.01
Total Assets	0.94	1.8
Accounts Payable	0.1	0.08
Accrued Expenses	0.14	0.09
Total Current Liabilities	0.24	0.17
Total Liabilities	0.24	0.17
Additional Paid-In Capital	5.16	4.74
Retained Earnings	-4.47	-3.11
Shareholders' Equity	0.7	1.63
Total Liabilities & Equity	0.94	1.8
Net Cash (Debt)	0.79	1.6
Net Cash Growth	-50.69%	-
Net Cash Per Share	47.57	112.00
Filing Date Shares Outstanding	0.15	0.15
Total Common Shares Outstanding	0.15	0.15
Working Capital	0.69	1.62
Book Value Per Share	4.67	10.91
Tangible Book Value	0.7	1.63
Tangible Book Value Per Share	4.67	10.91
Machinery	0.02	0.01

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q